Entera Bio's technology addresses the two major problem of oral drug delivery of large molecule APIs (active pharmaceutical ingredients). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract.

Entera's platform technology consists of two components combined to increase drug half-life and bioavailability. The first component is a proprietary molecular protection that prevents drug break down and significantly extends the half-life of drugs delivered in the gut. The second component is a proprietary synthetic amino acid that enables molecular transport of large molecules through the intestinal wall.

Currently, biological entities and other large molecules can only be delivered via injections and or other non-oral pathways. However, oral drug delivery is the easiest method for self-administering medications, has the greatest dosing flexibility, the highest compliance rates and is generally the most popular and user friendly form of drug administration. 

Entera protects its intellectual patent by a significant and growing patent portfolio.